One of the highest civilian awards in the country, the Padma Bhushan has been awarded to Dr Poonawalla for exceptional and distinguished service in trade and industry field.
“Health is one of the strongest pillars of the society and I will continue to work towards making it equitable for all,” Dr Cyrus Poonawalla, 81, the chairman and managing director of the Poonawalla group said while expressing his gratitude to the Government of India after being bestowed with the Padma Bhushan award.
One of the highest civilian awards in the country, the Padma Bhushan has been awarded to Dr Poonawalla for exceptional and distinguished service in trade and industry field. In his statement, Dr Poonawalla said, “It is a great privilege for me to be among the prestigious list of illustrious people who have contributed to the growth of the country.”
Dr Poonawalla founded the Pune-based Serum Institute of India (SII) in 1966 with the aim of manufacturing life saving immuno-biologicals in India which were in shortage in the country at that time and were being imported at high prices. SII went on to manufacture several life-saving biologicals at prices affordable to the common man and is now the world’s largest vaccine manufacturer by number of doses produced and sold globally.
The vaccines include those for polio, diphtheria, tetanus, pertussis, Hib, BCG, Hepatitis B, measles, mumps and rubella. It is estimated that about 65 per cent of the children in the world across 170 countries have received at least one vaccine manufactured by SII.
More recently, SII collaborated with the University of Oxford and the British-Swedish pharmaceutical company AstraZeneca to make the Covid-19 vaccine Covishield. Under the leadership of Dr Cyrus and Adar Poonawalla, Team Serum has been working tirelessly over the last several months to get Covishield vaccine doses. SII surpassed the 1.25-billion doses mark for Covishield and also resumed global distribution via the COVAX mechanism to low- and middle-income countries.
Adar Poonawalla congratulated all the deserving Padma awardees while colleagues close to Dr Cyrus Poonawalla applauded their visionary leader.
Adar Poonawalla took to Twitter to express gratitude to the Government of India for acknowledging “my mentor, my hero, my father Dr Cyrus Poonawalla” as he posted a picture of his father in his younger days.
Several close aides said that they were filled with pride at the honour, which was “long overdue”.
Dr Rajeev Dhere, executive director at SII, told The Indian Express, “I feel that this is a well-deserved award – We had hoped that Dr Cyrus would get the award much earlier. Still it is very apt that he has been awarded this year.” He added: “We are very happy to be part of the SII and proud that we have a visionary leader. He created a type of business model which is a workable, philanthropic one.”
It is the company’s philanthropic philosophy which is at the core of bringing down prices of newer vaccines such as Hepatitis-B to ensure that not just Indians but underprivileged children all over the world are protected birth onwards.
Last year, Dr Cyrus Poonawalla received the prestigious Lokmanya Tilak national award.
Source - The Indian Express
Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out
Adar Poonawalla awarded 'Business Leader of the Year' 2023 by the International Advertising Association (IAA) India Chapter
Cyrus Poonawalla Group appoints Keki Mistry as Strategic Advisor to all the Financial Services Ventures led by Adar Poonawalla
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.